- Home
- CIGL vs FBRX Comparison
CIGL vs FBRX Comparison
Compare CIGL & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CIGL | FBRX |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Singapore | United States |
| Employees | 134 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.7M | 487.2M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CIGL | FBRX |
|---|---|---|
| Price | $1.99 | $27.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 39.1K | ★ 385.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $6.50 |
| 52 Week High | $25.00 | $35.80 |
Technical Indicators
Market Signals| Indicator | CIGL | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 44.26 |
| Support Level | $1.55 | $26.67 |
| Resistance Level | $2.28 | $31.71 |
| Average True Range (ATR) | 0.16 | 3.16 |
| MACD | 0.01 | -0.26 |
| Stochastic Oscillator | 69.49 | 20.92 |
Price Performance
Historical ComparisonAbout CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.